|
Real-time Estimate
Cboe BZX
23:59:54 20/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 214.37 USD | -3.25% |
|
+2.21% | +22.34% |
| 08-13 | Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300 | MT |
| 08-11 | Global drugmakers invest billions to boost US presence | RE |
Company Valuation: Biogen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,242 | 39,877 | 37,495 | 22,283 | 25,818 | 32,736 | - | - |
| Change | - | 13.15% | -5.97% | -40.57% | 15.86% | 26.8% | - | - |
| Enterprise Value (EV) 1 | 37,820 | 40,560 | 43,384 | 26,204 | 28,289 | 37,673 | 35,156 | 32,084 |
| Change | - | 7.24% | 6.96% | -39.6% | 7.96% | 33.17% | -6.68% | -8.74% |
| P/E | 23.1x | 13.3x | 32.5x | 13.7x | 20x | 39.4x | 19.4x | 15.6x |
| PBR | 3.26x | 3.02x | 2.53x | 1.33x | 1.42x | 1.77x | 1.61x | 1.46x |
| PEG | - | 0x | -0.5x | 0.3x | -0.9x | -1.1x | 0x | 0.6x |
| Capitalization / Revenue | 3.21x | 3.92x | 3.81x | 2.3x | 2.61x | 3.14x | 3.07x | 2.99x |
| EV / Revenue | 3.44x | 3.99x | 4.41x | 2.71x | 2.86x | 3.61x | 3.3x | 2.93x |
| EV / EBITDA | 9.13x | 11.2x | 14.3x | 7.1x | 7.82x | 13.7x | 10.2x | 8.78x |
| EV / EBIT | 10.3x | 13.1x | 17x | 8.69x | 9.97x | 15x | 11x | 9.14x |
| EV / FCF | 11.2x | 35.5x | 34.2x | 9.63x | 13.8x | 20.3x | 14.8x | 11.8x |
| FCF Yield | 8.94% | 2.82% | 2.93% | 10.4% | 7.25% | 4.93% | 6.75% | 8.47% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | 5.628 | 11.41 | 14.22 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | 10,442 | 10,659 | 10,957 |
| EBITDA 1 | 4,144 | 3,618 | 3,040 | 3,689 | 3,618 | 2,740 | 3,453 | 3,656 |
| EBIT 1 | 3,656 | 3,099 | 2,545 | 3,015 | 2,838 | 2,514 | 3,203 | 3,509 |
| Net income 1 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | 953.1 | 1,899 | 2,247 |
| Net Debt 1 | 2,578 | 683 | 5,888 | 3,921 | 2,471 | 4,937 | 2,420 | -652.2 |
| Reference price 2 | 239.92 | 276.92 | 258.77 | 152.92 | 175.99 | 221.56 | 221.56 | 221.56 |
| Nbr of stocks (in thousands) | 146,893 | 144,001 | 144,898 | 145,719 | 146,702 | 147,754 | - | - |
| Announcement Date | 03/02/22 | 15/02/23 | 13/02/24 | 12/02/25 | 06/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 39.37x | 3.61x | 13.75x | -.--% | 32.74B | |
| 19.47x | 4.56x | 10.73x | 0.46% | 83.96B | |
| -20.3x | 31.29x | -20.21x | -.--% | 69.62B | |
| 19.51x | 4.2x | 12.95x | 2.53% | 56.76B | |
| 37.6x | 12.85x | 24.44x | -.--% | 51.35B | |
| 21.81x | 4.82x | 13.78x | 0.67% | 48.41B | |
| 56.59x | 3.67x | 28.41x | -.--% | 26.04B | |
| 72.78x | 7.05x | 47.2x | -.--% | 21.81B | |
| 24.4x | 5.23x | 13.63x | -.--% | 17.11B | |
| -30.56x | 17.28x | -46.07x | -.--% | 16.41B | |
| Average | 24.07x | 9.45x | 9.86x | 0.37% | 42.42B | |
| Weighted average by Cap. | 20.23x | 10.45x | 9.07x | 0.51% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIIB Stock
- Valuation Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
